L2HGDH

Across TCGA pan-cancer cohorts, L2HGDH mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated L2HGDH data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher L2HGDH mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated L2HGDH expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where L2HGDH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.591	0.890	<.001	32	view →
LSCC	DFS	Median	II,III,IV	1.000	0.830	.003	11	view →
CCRCC	OS	Tertile	III,IV	0.985	0.104	.024	8	view →
PDAC	OS	Median	IV	0.491	0.836	.024	6	view →
HNSC	OS	Median	All	0.619	0.790	.023	5	view →
UCEC	DFS	Median	II,III,IV	0.534	0.867	.044	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

L2HGDH–LUAD (OS)

Open the LUAD breakdown →